轻型缺血性脑卒中静脉溶栓疗效观察

赵瑞荣

【摘要】 目的 分析輕型缺血性脑卒中静脉溶栓治疗的疗效及安全性。方法 100例轻型缺血性脑卒中患者为研究对象， 采用同期对照法将患者分为研究组和对照组， 各50例。研究组根据患者发病时间采用阿替普酶或尿激酶静脉溶栓治疗， 对照组采用阿司匹林治疗。比较两组患者治疗前后的美国国立卫生研究院卒中量表（NIHSS） 评分， 住院时间及治疗后3个月的改良RANKIN量表（mRS） 评分， 治疗后致残、出血及再发性缺血性脑卒中发生情况。结果 治疗前， 两组患者的NIHSS评分对比， 差异无统计学意义（P>0.05）; 治疗后， 两组患者的NIHSS评分均较本组治疗前降低， 且研究组NIHSS评分为（1.21±0.34）分， 低于对照组的（2.46±0.46）分， 差异均具有统计学意义 （P<0.05）。研究组患者住院时间为（4.25±0.55）d， 短于对照组的（5.12±0.52）d， 差异具有统计学意义 （P<0.05）;治疗后3个月， 研究组患者mRS评分为（1.61±0.34）分， 低于对照组的（2.18±0.42）分， 差异具有统计学意义（P<0.05）。研究组残疾率为6.0%， 低于对照组的20.0%， 差异具有统计学意义（P<0.05）;研究组出血率为0、再发性缺血性脑卒中发生率为4.0%， 对照组出血率为0、再发性缺血性脑卒中发生率为4.0%， 对比差异均无统计学意义（P>0.05）。结论 对轻型缺血性脑卒中患者积极采取静脉溶栓治疗， 有利于改善其神经功能缺损情况， 利于患者预后， 适用于临床。

【关键词】 轻型缺血性脑卒中;静脉溶栓;阿替普酶;尿激酶

DOI：10.14163/j.cnki.11-5547/r.2019.17.001

Observation on efficacy of mild ischemic stroke   ZHAO Rui-rong. Dongguan Kanghua Hospital， Dongguan 523000， China

【Abstract】 Objective   To analyze the efficacy and safety of intravenous thrombolytic therapy for mild ischemic stroke. Methods   A total of 100 mild ischemic stroke patients as study subjects were divided into research group and control group according to synchronized control method， with 50 cases in each group. The research group was treated by intravenous thrombolysis with ateplase or urokinase according to the time of onset， and the control group was treated with aspirin. Comparison were made on National Institutes of Health Stroke scale （NIHSS） score， hospitalization time， modified RANKIN scale （mRS） score at 3 months after treatment， occurrence of disability， bleeding and recurrent ischemic stroke after treatment between the two groups. Results   Before treatment， both groups had no statistically significant difference in NIHSS score （P>0.05）. After treatment， both groups had lower NIHSS score than that before treatment， and the research group had lower NIHSS score as （1.21±0.34） points than （2.46±0.46） points in the control group. Their difference was statistically significant （P<0.05）. The research group had shorter hospitalization time as （4.25±0.55） d than （5.12±0.52） d in the control group， and the difference was statistically significant （P<0.05）. After 3 months of treatment， the research group had lower mRS score as （1.61±0.34） points than （2.18±0.42） points in the control group， and the difference was statistically significant （P<0.05）. The research group had lower disability rate as 6.0% than 20.0% in the control group， and the difference was statistically significant （P<0.05）. The research group had bleeding rate as 0， incidence of recurrent ischemic stroke as 4.0%， which were 0 and 4.0% in the control group. Their difference was not statistically significant （P>0.05）. Conclusion   Intravenous thrombolytic therapy for mild ischemic stroke patients is beneficial to improve the neurological deficits and prognosis. It is suitable for clinical application.